Beta Bionics (NASDAQ:BBNX) Stock: Insider Christy Jones Sells 6,430 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) Director Christy Jones sold 6,430 shares of Beta Bionics stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $23.00, for a total value of $147,890.00. Following the sale, the director owned 19,564 shares in the company, valued at $449,972. This trade represents a 24.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beta Bionics Stock Down 1.9%

Shares of NASDAQ BBNX opened at $21.76 on Friday. The business has a 50-day moving average price of $18.08 and a 200 day moving average price of $14.37. The stock has a market cap of $978.98 million, a PE ratio of -13.19 and a beta of 3.37. Beta Bionics, Inc. has a 52-week low of $8.80 and a 52-week high of $32.71.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $32.01 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. Sell-side analysts anticipate that Beta Bionics, Inc. will post -2.06 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on BBNX. Truist Financial increased their target price on shares of Beta Bionics from $23.00 to $28.00 and gave the stock a “buy” rating in a research note on Thursday. The Goldman Sachs Group lifted their price objective on shares of Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Robert W. Baird boosted their price objective on shares of Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday, September 15th. Weiss Ratings upgraded shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Finally, Leerink Partners lifted their target price on shares of Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a report on Monday, September 14th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Beta Bionics presently has an average rating of “Moderate Buy” and a consensus target price of $22.91.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Wells Fargo initiated coverage of Beta Bionics with an “overweight” rating and a $28 price target. Truist Financial also raised its target from $23 to $28 and maintained a “buy” rating, implying potential upside from the recently reported trading level. Analyst coverage and price targets
• Neutral Sentiment: Several law firms—including Robbins LLP, Faruqi & Faruqi, Rosen Law Firm, Pomerantz, Kaplan Fox and others—publicized the same securities class action and reminded investors of the November 3, 2026 deadline to seek lead-plaintiff status. The repeated notices do not represent new allegations, but they increase attention around the litigation. Faruqi securities class action deadline notice
• Negative Sentiment: The lawsuit alleges that Beta Bionics failed to disclose or adequately describe FDA concerns, including a June 2025 Form 483 and more than 18,000 complaints involving the iLet insulin-delivery system. The allegations are unproven, but potential regulatory, reputational and legal costs are weighing on investor sentiment. Johnson Fistel Beta Bionics investor alert
• Negative Sentiment: Director Christy Jones sold 6,430 shares for approximately $147,890, reducing her position by about 24.7%. The transaction was executed under a pre-arranged Rule 10b5-1 plan, which makes it a weaker discretionary bearish signal, but it nevertheless adds to reported insider-selling activity. SEC Form 4 insider-sale filing

Institutional Investors Weigh In On Beta Bionics

Several institutional investors have recently made changes to their positions in BBNX. Caitong International Asset Management Co. Ltd increased its holdings in shares of Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after purchasing an additional 1,818 shares in the last quarter. Legal & General Group Plc acquired a new position in Beta Bionics during the second quarter worth about $62,000. The Manufacturers Life Insurance Company purchased a new position in Beta Bionics in the second quarter valued at about $172,000. ProShare Advisors LLC acquired a new stake in shares of Beta Bionics during the 4th quarter valued at approximately $217,000. Finally, Ieq Capital LLC purchased a new stake in shares of Beta Bionics during the 2nd quarter worth approximately $229,000.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.